Nakamura Katsunori

写真a

Title

Professor

Researcher Number(JSPS Kakenhi)

20361363
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Faculty of Medicine   University Hospital   Professor  

To the head of this page.▲

Graduate School 【 display / non-display 】

  • 1989
    -
    1994

    Hokkaido University  Graduate School, Division of Food and Medical Sciences  Other  Other

  • 1994
    -
    1996

    Hokkaido University  Graduate School, Division of Pharmaceutical Sciences  Master's Course  Other

  • 1996
    -
    1999

    Hokkaido University  Graduate School, Division of Pharmaceutical Sciences  Doctor's Course  Other

To the head of this page.▲

Study abroad experiences 【 display / non-display 】

  • 1999.04
    -
    2001.03

    Vanderbilt University, Postdoctoral fellow  

To the head of this page.▲

External Career 【 display / non-display 】

  • 1900.01
    　
    　

    Work supervised by Professor Dr. Fred. P. Guengerich  

  • 1998.04
    -
    1999.03

    Japan Society for the Promotion of Science Research Fellow  

  • 2001.04
    -
    2003.03

    Gunma University Hospital, Pharmacist  

  • 2003
    　
    　

    - Assistant Professor of Department of of Clinical Pharmacology, Gunma University School of  

  • 2003
    　
    　

     

display all >>

To the head of this page.▲

Affiliated academic organizations 【 display / non-display 】

  • 1994.04
    -
    Now
     

    The Pharmaceutical Society of Japan 

  • 1994.04
    -
    Now
     

    The Japanese Society of Clinical Pharmacology and Therapeutics 

  • 1999.04
    -
    Now
     

    International Society for the Study of Xenobiotics 

  • 2001.04
    -
    Now
     

    Japanese Society of Pharmaceutical Health and Science 

  • 2010.04
    -
    2012.03
     

    The Pharmaceutical Society of Japan 

display all >>

To the head of this page.▲

Research Interests 【 display / non-display 】

  • Drug metabolism,Pharmacogenetics,Personalized medicine

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life Science / Clinical pharmacy

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Effects of 5-fluorouracil Co-administration on Blood Pressure in Patients Maintained on Antihypertensives: a Retrospective Case Series.

    Tayag JCS, Ishii T, Kokuba S, Hirata T, Shiohira H, Nakamura K

    Die Pharmazie ( Die Pharmazie )  78 ( 5 ) 67 - 75   2023.05 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Warfarin Drug-Drug Interactions with Amiodarone and Tramadol in a Patient with Paroxysmal Atrial Fibrillation: A Case Report

    Higa Marina, Katsuren Eisuke, Tayag Jose Carlos S., Iwabuchi Masashi, Ohya Yusuke, Shiohira Hideo, Nakamura Katsunori

    BPB Reports ( 公益社団法人 日本薬学会 )  6 ( 3 ) 98 - 102   2023 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    <p>Amiodarone and tramadol are known to have drug-drug interactions that potentiate the effects of the anticoagulant warfarin. Herein we report a case which suggests increasing prothrombin time-international normalized ratio (PT-INR) and PT-INR/dose ratio due to the concomitant administration of warfarin, amiodarone (a cytochrome P450 2C9 inhibitor) and tramadol (an enhancer of anticoagulant effects of warfarin). A 72-year-old woman underwent emergency surgery following a suspected non-obstructive mesenteric ischemia, and diagnosis was confirmed. After surgery, the patient was given 2 mg/day of WF, and tramadol/acetaminophen, followed by amiodarone. After the concomitant dose of the triple combination, the PT-INR increased to over 7.02 (above the upper limit of the laboratory). The physician consulted the pharmacist for dose adjustment, and the pharmacist recommended a reduction in the dose to 0.5 mg. After restarting warfarin, PT-INR was controlled to 1.66–2.02. However, the PT-INR/dose ratio increased from 1.22 to 3.32–4.04 compared to the initial dose. The results suggest that these enhanced anticoagulant effects may be due to the inhibition of WF metabolism. Although the patient underwent resection of the small intestine, the effects of oral vitamin K1 were observed one day after administration. In conclusion, frequent PT-INR monitoring, and pharmacist intervention such as the assessment and dose adjustment in this report should be beneficial during anticoagulation therapy when multiple concomitant medications with suspected drug-drug interactions are present.</p>

  • High-dose methotrexate therapy for a child with B-cell precursor acute lymphoblastic leukemia and congenital solitary kidney.

    Hokama N, Hyakuna N, Hamada S, Shiohira H, Nakanishi K, Nakamura K

    Pediatric blood & cancer ( Pediatric Blood and Cancer )  69 ( 8 ) e29567   2022.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Successive disappearance of summer influenza in the Okinawa prefecture during the severe acute respiratory syndrome coronavirus 2 pandemic.

    Sunagawa S, Iha Y, Kinjo T, Nakamura K, Fujita J

    Respiratory investigation ( Respiratory Investigation )  60 ( 1 ) 184 - 186   2022.01 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Changes in Pharmacodynamic Parameters during Co-administration of 5-FU with Warfarin: A Retrospective Case Series.

    Tayag JCS, Ishii T, Kokuba S, Hirata T, Shiohira H, Nakamura K

    Biological & pharmaceutical bulletin ( 公益社団法人 日本薬学会 )  45 ( 8 ) 1101 - 1105   2022 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    <p>Drug–drug interactions (DDIs) between warfarin (WF) and fluoropyrimidines are well known. Co-administration of WF and 5-fluorouracil (5-FU) leads to elevations in prothrombin time international normalised ratio (PT-INR). The inhibition of drug metabolism through suppression of CYP activity is a possible cause of prolonged PT-INR elevations. 5-FU and its metabolites are suspected to inhibit CYPs, but the precise mechanisms of action remain unknown. This study aimed to investigate the possible DDI effects of the co-administration of 5-FU with WF using PT-INR and PT-INR/dose ratio as pharmacodynamic parameters. Retrospective case series data were collected from patients who received parenteral 5-FU chemotherapy from April 2009 to December 2019 at the University of the Ryukyus Hospital. Seven patients who received 5-FU in combination with WF were analysed. There was a significant increase in PT-INR and PT-INR/dose during the co-administration of WF and 5-FU (<i>p</i> = 0.0018 and <i>p</i> = 0.0187, respectively; paired <i>t</i>-test). The findings demonstrated significant DDI between 5-FU and WF evident as elevated PT-INR and PT-INR/dose ratio.</p>

display all >>

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

To the head of this page.▲

Preferred joint research theme 【 display / non-display 】

  • Community medicine pharmacy

    Community medicine pharmacy

  • Drug metabolism and toxicity

    Toxicology

  • Personalized medicine

    Pharmacogenetics

To the head of this page.▲

SDGs 【 display / non-display 】

  • 生薬や漢方薬の医薬品との相互作用に関する研究

To the head of this page.▲